MExbrain

Focus: MExbrain is a French biotech developing biopolymer treatments targeting metal toxicity conditions, with a focus on neurology and critical care applications.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About MExbrain

AI assessmentNot Hiring

No open roles listed right now. Follow MExbrain to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MEX-CD1 Dialysis

Acute on Chronic Liver Failure

N/A

Clinical Trials (1)

NCT06340269Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF

N/A

Help build intelligence for MExbrain

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in an emerging therapeutic area (metal toxicity via biopolymers) with limited competition
Location in Villeurbanne, France provides access to EU regulatory pathways and academic partnerships
Early-stage pipeline targeting severe conditions (acute liver failure, Wilson's disease, myelodysplastic syndrome) with high unmet need

Watch Out For

No active job openings currently listed signals limited hiring and potential resource constraints
Pre-clinical/early-stage pipeline with only 1 active trial and undefined phase progression creates execution risk
Lack of disclosed funding, revenue, and employee count raises concerns about financial runway and organizational stability

Generated by Claude from MExbrain's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Low-volume continuous veno-venous haemodialysis

Hepatolenticular Degeneration; Wilson

N/A

Trace Elements Concentration in Dialysis

Dialysis

N/A

Low-volume continuous veno-venous haemodialysis with MEX-CD1 use

Myelodysplastic Syndrome

N/A